There are no published, direct randomized controlled trials on the combination of GLP-1 medications and intermittent fasting
Evidence boundary No published human randomized trial has evaluated long-term injectable GHK-Cu for skin, hair, or wound endpoints
Be Aware of Any Unwanted Side Effects During this gradual increase in dosage, patients should be aware of any unwanted side effects, such as: Excessive feelings of fullness that go beyond the desired results
Its administration after spinal cord injuries has been associated with improved neuronal recovery and better motor function, highlighting its potential as a therapeutic agent in neurorehabilitation
About 1 in 8 Americans uses GLP-1 drugs for diabetes, weight loss and other chronic conditions, including semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)
A class of new medications called hemoglobin S (HbS) polymerization inhibitors (e.g., voxelotor), has been recently approved by the FDA in 2019 and by the E.U